109 related articles for article (PubMed ID: 15514986)
1. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution.
Zhang Y; Roy S; Jones LS; Krishnan S; Kerwin BA; Chang BS; Manning MC; Randolph TW; Carpenter JF
J Pharm Sci; 2004 Dec; 93(12):3076-89. PubMed ID: 15514986
[TBL] [Abstract][Full Text] [Related]
2. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist.
Roy S; Katayama D; Dong A; Kerwin BA; Randolph TW; Carpenter JF
Biochemistry; 2006 Mar; 45(12):3898-911. PubMed ID: 16548517
[TBL] [Abstract][Full Text] [Related]
3. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
Roy S; Jung R; Kerwin BA; Randolph TW; Carpenter JF
J Pharm Sci; 2005 Feb; 94(2):382-96. PubMed ID: 15614819
[TBL] [Abstract][Full Text] [Related]
4. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor.
Thirumangalathu R; Krishnan S; Brems DN; Randolph TW; Carpenter JF
J Pharm Sci; 2006 Jul; 95(7):1480-97. PubMed ID: 16729274
[TBL] [Abstract][Full Text] [Related]
5. Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange.
Alford JR; Fowler AC; Wuttke DS; Kerwin BA; Latypov RF; Carpenter JF; Randolph TW
J Pharm Sci; 2011 Oct; 100(10):4215-24. PubMed ID: 21557223
[TBL] [Abstract][Full Text] [Related]
6. Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist.
Chi EY; Kendrick BS; Carpenter JF; Randolph TW
J Pharm Sci; 2005 Dec; 94(12):2735-48. PubMed ID: 16258998
[TBL] [Abstract][Full Text] [Related]
7. Anion binding and controlled aggregation of human interleukin-1 receptor antagonist.
Raibekas AA; Bures EJ; Siska CC; Kohno T; Latypov RF; Kerwin BA
Biochemistry; 2005 Jul; 44(29):9871-9. PubMed ID: 16026159
[TBL] [Abstract][Full Text] [Related]
8. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution.
Chang BS; Beauvais RM; Arakawa T; Narhi LO; Dong A; Aparisio DI; Carpenter JF
Biophys J; 1996 Dec; 71(6):3399-406. PubMed ID: 8968609
[TBL] [Abstract][Full Text] [Related]
9. Role of benzyl alcohol in the unfolding and aggregation of interferon α-2a.
Bis RL; Singh SM; Cabello-Villegas J; Mallela KM
J Pharm Sci; 2015 Feb; 104(2):407-15. PubMed ID: 25100180
[TBL] [Abstract][Full Text] [Related]
10. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state.
Kendrick BS; Chang BS; Arakawa T; Peterson B; Randolph TW; Manning MC; Carpenter JF
Proc Natl Acad Sci U S A; 1997 Oct; 94(22):11917-22. PubMed ID: 9342337
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of lysozyme by benzyl alcohol: surface tension and thermodynamic parameters.
Goyal MK; Roy I; Amin A; Banerjee UC; Bansal AK
J Pharm Sci; 2010 Oct; 99(10):4149-61. PubMed ID: 20310022
[TBL] [Abstract][Full Text] [Related]
12. Role of benzyl alcohol in the prevention of heat-induced aggregation and inactivation of hen egg white lysozyme.
Goyal MK; Roy I; Banerjee UC; Sharma VK; Bansal AK
Eur J Pharm Biopharm; 2009 Feb; 71(2):367-76. PubMed ID: 18929648
[TBL] [Abstract][Full Text] [Related]
13. Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.
Sorret LL; DeWinter MA; Schwartz DK; Randolph TW
Protein Sci; 2018 Jul; 27(7):1191-1204. PubMed ID: 29388282
[TBL] [Abstract][Full Text] [Related]
14. Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation.
Chang BS; Beauvais RM; Dong A; Carpenter JF
Arch Biochem Biophys; 1996 Jul; 331(2):249-58. PubMed ID: 8660705
[TBL] [Abstract][Full Text] [Related]
15. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors.
Svenson M; Nedergaard S; Heegaard PM; Whisenand TD; Arend WP; Bendtzen K
Eur J Immunol; 1995 Oct; 25(10):2842-50. PubMed ID: 7589081
[TBL] [Abstract][Full Text] [Related]
16. High-pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: thermodynamics, kinetics, and application to accelerated formulation studies.
Seefeldt MB; Kim YS; Tolley KP; Seely J; Carpenter JF; Randolph TW
Protein Sci; 2005 Sep; 14(9):2258-66. PubMed ID: 16081653
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications.
Bendele A; Colloton M; Vrkljan M; Morris J; Sabados K
J Lab Clin Med; 1995 Apr; 125(4):493-500. PubMed ID: 7706905
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat.
Loddick SA; Rothwell NJ
J Cereb Blood Flow Metab; 1996 Sep; 16(5):932-40. PubMed ID: 8784237
[TBL] [Abstract][Full Text] [Related]
19. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics.
Alford JR; Kendrick BS; Carpenter JF; Randolph TW
J Pharm Sci; 2008 Aug; 97(8):3005-21. PubMed ID: 17924426
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo.
Qian L; Xiang D; Zhang J; Zhu S; Gao J; Wang X; Gao J; Zhang Y; Shen J; Yu Y; Han W; Wu M
Biomed Pharmacother; 2013 Mar; 67(2):108-15. PubMed ID: 23433850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
